Galapagos and CRT Announce Anti-Cancer Drug Discovery Collaboration
News Jan 20, 2006
Under the terms of the agreement Galapagos' service division BioFocus will perform medicinal chemistry services on a series of CRT anti-cancer drug programs.
In return, CRT will fund the work of four BioFocus scientists throughout 2006.
"This agreement testifies to the high quality of BioFocus' medicinal chemistry expertise and the overall competitiveness of our integrated services portfolio," said Onno van de Stolpe, CEO of Galapagos.
"We also are pleased to assist Cancer Research Technology in the fight against cancer."
"CRT has succeeded in forming a number of collaborative anti-cancer programs with academic and commercial partners alike," added Tony Raynham, CRT's Head of Medicinal Chemistry.
"Our relationship with BioFocus, in conjunction with existing in-house R&D resource, will ensure that these programs are advanced rapidly through early-stage development, thereby creating robust licensing opportunities and cancer patient benefit."
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019